3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
4
Multiple Myeloma
2
Vaccinia
1
Transplant-Related Hematologic Malignancy
1
Recurrence
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Hodgkin Disease
1
Glioma
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Interventions
Carboplatin
3
durvalumab
2
Tretinoin
2
Paclitaxel
2
Irinotecan
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
90 days
×
Clear all
No trials found.